MChristine Jacobs - McKesson Independent Director
| MCK Stock | USD 628.50 2.12 0.34% |
Director
Ms. M. Christine Jacobs is an Independent Director of the Company since January 1999. Ms. Jacobs, age 67, retired from Theragenics Corporationrationration, a manufacturer of prostate cancer treatment devices and surgical products, in 2013, having served as its Chairman, President and Chief Executive Officer. She held the position of Chairman from 2007 to 2013, and previously from 1998 to 2005. She was CoChairman of the Board from 1997 to 1998 and was elected President in 1992 and Chief Executive Officer in 1993. Ms. Jacobs was a director of the Company since January 1999. Having led a public company within the healthcare industry for over 20 years, Ms. Jacobs brings to our Board significant relevant industry experience and a keen understanding of and strong insight into issues, challenges and opportunities facing the Company, including those related to legislative healthcare initiatives. As Chairman and Chief Executive Officer of Theragenics Corporationrationration, she was at the forefront of her company in regard to the evolving corporate governance environment, which enables her to provide ongoing valuable contributions as a member of the Governance Committee of our Board since 1999.
| Age | 68 |
| Tenure | 25 years |
| Address | 6555 State Highway 161, Irving, TX, United States, 75039 |
| Phone | 972 446 4800 |
| Web | https://www.mckesson.com |
McKesson Management Efficiency
The company has Return on Asset of 0.0392 % which means that on every $100 spent on assets, it made $0.0392 of profit. This is way below average. McKesson's management efficiency ratios could be used to measure how well McKesson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.27 this year, although the value of Return On Tangible Assets will most likely fall to 0.04. At this time, McKesson's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 17.5 B this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 36.5 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Trudi Allcott | Owens Minor | N/A | |
| Michael Riordan | Owens Minor | 61 | |
| Bruce Downey | Cardinal Health | 72 | |
| John Losh | Cardinal Health | 73 | |
| Steven Paladino | Henry Schein | 67 | |
| Akhil Johri | Cardinal Health | 59 | |
| Colleen Arnold | Cardinal Health | 61 | |
| Eddie Moore | Owens Minor | 71 | |
| Mark McGettrick | Owens Minor | 63 | |
| Mark Mlotek | Henry Schein | 68 | |
| Carrie Cox | Cardinal Health | 62 | |
| Nancy Killefer | Cardinal Health | 66 | |
| Gwendolyn Bingham | Owens Minor | 61 | |
| Patricia Hall | Cardinal Health | 67 | |
| Calvin Darden | Cardinal Health | 69 | |
Management Performance
| Return On Asset | 0.0392 |
McKesson Leadership Team
Elected by the shareholders, the McKesson's board of directors comprises two types of representatives: McKesson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of McKesson. The board's role is to monitor McKesson's management team and ensure that shareholders' interests are well served. McKesson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, McKesson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lori Schechter, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Holly Weiss, VP Relations | ||
| Pete Slone, Senior Affairs | ||
| W Dunbar, Independent Director | ||
| Bradley Lerman, Independent Director | ||
| LeAnn Smith, Executive Officer | ||
| Kenneth Washington, Independent Director | ||
| M Jacobs, Independent Director | ||
| Kirk Kaminsky, President Business | ||
| Edward Mueller, Independent Chairman of the Board | ||
| Nancy Avila, Chief VP | ||
| James Hinton, Director | ||
| Richard Carmona, Independent Director | ||
| Marie Knowles, Independent Director | ||
| N Coles, Independent Director | ||
| Linda Mantia, Independent Director | ||
| Nancy Flores, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Tracy Faber, Chief Human Resource Officer, Executive Vice President | ||
| Susan Salka, Independent Director | ||
| Kevin Emerson, Interim Senior Vice President Chief Accounting Officer, Controller | ||
| Tom Rodgers, Executive Vice President and Chief Strategy and Business Development Officer | ||
| Paul Smith, Senior Taxes | ||
| Donald Knauss, Independent Director | ||
| Maria Martinez, Independent Director | ||
| Michele JD, Executive Officer | ||
| Brad Lerman, Independent Director | ||
| Kathleen Thompson, Director | ||
| Rachel Rodriguez, Vice Relations | ||
| Michele Lau, Executive Officer | ||
| Britt Vitalone, Chief Financial Officer, Executive Vice President | ||
| Thomas MBA, Executive Officer | ||
| Britt CPA, Executive CFO | ||
| Napoleon Rutledge, Senior Vice President Chief Accounting Officer, Controller | ||
| Francisco Fraga, Chief VP | ||
| Brian Tyler, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| MChristine Jacobs, Independent Director | ||
| Lori JD, Board Advisor | ||
| Dominic Caruso, Independent Director |
McKesson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is McKesson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0392 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 84.22 B | ||||
| Shares Outstanding | 126.94 M | ||||
| Shares Owned By Institutions | 88.90 % | ||||
| Number Of Shares Shorted | 2.09 M | ||||
| Price To Earning | 26.98 X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.24 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in McKesson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy McKesson Stock please use our How to buy in McKesson Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of McKesson. If investors know McKesson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about McKesson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Dividend Share 2.57 | Earnings Share 19.36 | Revenue Per Share 2.5 K | Quarterly Revenue Growth 0.213 |
The market value of McKesson is measured differently than its book value, which is the value of McKesson that is recorded on the company's balance sheet. Investors also form their own opinion of McKesson's value that differs from its market value or its book value, called intrinsic value, which is McKesson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because McKesson's market value can be influenced by many factors that don't directly affect McKesson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between McKesson's value and its price as these two are different measures arrived at by different means. Investors typically determine if McKesson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, McKesson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.